Holen Sie sich die Stockscreener-App
5.73
3.80%
0.21
Schlusskurs vom Vortag:
$5.52
Offen:
$5.55
24-Stunden-Volumen:
900.55K
Relative Volume:
0.70
Marktkapitalisierung:
$792.10M
Einnahmen:
$62.04M
Nettoeinkommen (Verlust:
$-533.34M
KGV:
-1.4617
EPS:
-3.92
Netto-Cashflow:
$-473.07M
1W Leistung:
+8.11%
1M Leistung:
+9.56%
6M Leistung:
-45.58%
1J Leistung:
-43.55%
1-Tages-Spanne:
$5.55
$5.74
1-Wochen-Bereich:
$5.26
$5.98
52-Wochen-Spanne:
$4.32
$14.45
Vir Biotechnology Inc Stock (VIR) Company Profile
Firmenname
Vir Biotechnology Inc
Sektor
Branche
Telefon
415-906-4324
Adresse
1800 OWENS STREET, SAN FRANCISCO, CA
Vergleichen Sie VIR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
5.73 | 732.66M | 62.04M | -533.34M | -473.07M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-01-29 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-03-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Hochstufung | Goldman | Neutral → Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Eingeleitet | SVB Leerink | Outperform |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Underweight |
| 2022-03-03 | Hochstufung | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Herabstufung | Goldman | Buy → Neutral |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-01-27 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-05 | Eingeleitet | BofA Securities | Buy |
| 2020-09-14 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-11 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Eingeleitet | Needham | Buy |
| 2020-03-19 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2020-02-27 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2019-11-05 | Eingeleitet | Barclays | Overweight |
| 2019-11-05 | Eingeleitet | Cowen | Outperform |
| 2019-11-05 | Eingeleitet | Goldman | Buy |
| 2019-11-05 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Vir Biotechnology Inc Aktie (VIR) Neueste Nachrichten
Vir Biotechnology Inc. Stock Analysis and ForecastFree Capital Efficiency Planning - Autocar Professional
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2025 Financial Results on August 6, 2025 - Business Wire
Is Vir Biotechnology Inc. a good long term investmentSuperior investment outcomes - jammulinksnews.com
What analysts say about Vir Biotechnology Inc. stockFree Capital Allocation Plans - jammulinksnews.com
What drives Vir Biotechnology Inc. stock priceFree Bull & Bear Market Updates - printweek.in
(VIR) Investment Analysis and Advice - news.stocktradersdaily.com
Vir Biotechnology EVP Eisner sells $57k in stock By Investing.com - Investing.com Canada
Biotech IPO For The Week Ahead - RTTNews
Raymond James Initiates Vir Biotechnology(VIR.US) With Buy Rating, Announces Target Price $12 - 富途牛牛
Where Vir Biotechnology Stands With Analysts - Benzinga
Raymond James Initiates Vir Biotechnology at Outperform With $12 Price Target - MarketScreener
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock? - Yahoo Finance
Unraveling Vir Biotechnology's 10.6% Spike: A Technical Deep Dive - AInvest
Unraveling Vir Biotechnology's 8.8% Surge: A Deep Dive - AInvest
How to Take Advantage of moves in (VIR) - news.stocktradersdaily.com
Vir Biotechnology Insiders Sell US$1.1m Of Stock, Possibly Signalling Caution - simplywall.st
Hepatitis D Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Long Term Trading Analysis for (VIR) - news.stocktradersdaily.com
Transcript : Vir Biotechnology, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 04 - MarketScreener
(VIR) Trading Advice - news.stocktradersdaily.com
Vir Biotechnology director Janet Napolitano sells $16,148 in stock - Investing.com Australia
Vir Biotechnology director Janet Napolitano sells $16,148 in stock By Investing.com - Investing.com UK
Vir Biotechnology Holds 2025 Annual Stockholder Meeting - TipRanks
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - BioSpace
Vir Biotechnology to Participate in the Goldman Sachs 46th Annua - GuruFocus
Vir Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 | VIR Stock News - GuruFocus
Vir Biotech at TD Cowen’s Summit: Strategic Focus on HDV and Oncology - Investing.com
Gilead Ready To Go After Hepatitis D Again - insights.citeline.com
Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga
Vir Biotechnology (VIR) Maintains 'Buy' Rating with $14 Price Ta - GuruFocus
Vir Biotechnology (VIR) Maintains 'Buy' Rating with $14 Price Target | VIR Stock News - GuruFocus
Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit - BioSpace
Vir Biotechnology stock target cut to $15 by H.C. Wainwright - Investing.com Australia
Vir Biotechnology to Participate in TD Cowen 6th Annual Oncology Innovation Summit | VIR Stock News - GuruFocus
Vir Biotechnology’s SWOT analysis: HDV treatment potential lifts stock outlook - Investing.com Australia
Finanzdaten der Vir Biotechnology Inc-Aktie (VIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vir Biotechnology Inc-Aktie (VIR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Eisner Mark | EVP and Chief Medical Officer |
Jul 17 '25 |
Sale |
5.47 |
3,586 |
19,629 |
104,618 |
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):